Atrial Natriuretic Peptide as a Biomarker and Therapeutic Target in Cancer: A Focus on Colorectal Cancer

Q3 Medicine Current Signal Transduction Therapy Pub Date : 2024-03-11 DOI:10.2174/0115743624292634240223094729

S. Mehrabadi, Mahla Velayati, Nima Zafari, S. Mollazadeh, Amir Avan

{"title":"Atrial Natriuretic Peptide as a Biomarker and Therapeutic Target in\nCancer: A Focus on Colorectal Cancer","authors":"S. Mehrabadi, Mahla Velayati, Nima Zafari, S. Mollazadeh, Amir Avan","doi":"10.2174/0115743624292634240223094729","DOIUrl":null,"url":null,"abstract":"\n\nOne of the most prevalent cancers throughout the world is colorectal cancer (CRC).\nNatriuretic peptides are important hormones that have a crucial role in the physiology of humans\nand other animals. There are a variety of treatments for colon cancer. However, conventional\ntherapies have many side effects and low efficacy in the treatment of this disease. Atrial Natriuretic\nPeptide (ANP) is one of the most well-known natriuretic peptides involved in regulating\nblood pressure and blood volume. Studies have demonstrated that ANP has a therapeutic effect\non different cancer types. The anti-tumor effect of ANP is exerted by inhibiting DNA synthesis\nbut not inducing apoptosis. The anti-proliferative role of ANP has been reported in human\nbreast, prostate, colon, pancreatic, lung, and ovarian cancer and in many other tumors. Therefore,\nwe review the recent papers on natriuretic peptides in CRC as a common malignancy in\nadults to assess the pathways of ANP involved in the progression of CRC and its effects on the\nprevention or treatment of CRC and other cancer types.\n","PeriodicalId":10868,"journal":{"name":"Current Signal Transduction Therapy","volume":"47 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Signal Transduction Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115743624292634240223094729","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

One of the most prevalent cancers throughout the world is colorectal cancer (CRC). Natriuretic peptides are important hormones that have a crucial role in the physiology of humans and other animals. There are a variety of treatments for colon cancer. However, conventional therapies have many side effects and low efficacy in the treatment of this disease. Atrial Natriuretic Peptide (ANP) is one of the most well-known natriuretic peptides involved in regulating blood pressure and blood volume. Studies have demonstrated that ANP has a therapeutic effect on different cancer types. The anti-tumor effect of ANP is exerted by inhibiting DNA synthesis but not inducing apoptosis. The anti-proliferative role of ANP has been reported in human breast, prostate, colon, pancreatic, lung, and ovarian cancer and in many other tumors. Therefore, we review the recent papers on natriuretic peptides in CRC as a common malignancy in adults to assess the pathways of ANP involved in the progression of CRC and its effects on the prevention or treatment of CRC and other cancer types.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

作为癌症生物标志物和治疗靶点的心房钠尿肽：聚焦结直肠癌

Natriuretic peptides 是一种重要的激素，在人类和其他动物的生理机能中起着至关重要的作用。结肠癌有多种治疗方法。然而，传统疗法副作用大、疗效低。心房钠尿肽（ANP）是最著名的钠尿肽之一，参与调节血压和血容量。研究表明，ANP 对不同类型的癌症有治疗作用。ANP 的抗肿瘤作用是通过抑制 DNA 合成而不是诱导细胞凋亡来实现的。ANP 在人类乳腺癌、前列腺癌、结肠癌、胰腺癌、肺癌和卵巢癌以及许多其他肿瘤中的抗增殖作用已有报道。因此，我们综述了近期有关作为常见恶性肿瘤的 CRC 中的钠尿肽的论文，以评估 ANP 参与 CRC 进展的途径及其对 CRC 和其他癌症类型的预防或治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Signal Transduction Therapy 医学-药学

CiteScore

1.70

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders. The journal publishes timely in-depth reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.